Immunotherapy by BCG against prostate adenocarcinomas in anatomical compartments.
The prostate adenocarcinoma-III (PA-III) cell line manifests a high rate of metastasis from the SC tumor site through lymphatic channels to the lungs in which they produce visible focal tumors. i.v. inoculation of BCG interfered with the passage of PA-III cells to the lungs; but not if the BCG was inoculated IP. IP inoculation of BCG suppressed propagation of PA-III cells in the peritoneal cavity, but there was no effect on metastasis of PA-III cells from a SC PA-III tumor to the lungs. Inoculation of BCG did not induce a systemic anticancer effect unless PA-III cells and BCG occupied the same anatomical compartment. Two compartments are described: intravascular and intraperitoneal.
Pollard
M
M
Lobund Laboratory, University of Notre Dame, IN 46556.
Luckert
P H
PH
D000230:Adenocarcinoma / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D002460:Cell Line; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000556:secondary* / Q000628:therapy*; D008297:Male; D009163:Mycobacterium bovis / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D051381:Rats; D011919:Rats, Inbred Strains
D001500:BCG Vaccine